Inventors: Starkebaum and Prentice

Docket No.: P-11296.00

CLAIMS:

1. A method for reducing stomach acid secretion comprising:

determining a first acid level of a patient with a hyperacid condition;

ablating tissue within a stomach with an ablation probe sized to fit the stomach to

inhibit the production of acid by the tissue; and

determining a second acid level of the patient following a period of time after

ablation.

2. The method for reducing stomach acid secretion of claim 1, wherein determining the

first acid level comprises monitoring acid reflux levels with an esophageal pH monitor.

3. method for reducing stomach acid secretion of claim 1, wherein the first and second

acid levels are first and second esophageal acid levels.

4. The method for reducing stomach acid secretion of claim 1, wherein inhibiting the

production of stomach acid comprises reducing an amount of acid refluxed into an esophagus

of the patient.

5. The method for reducing stomach acid secretion of claim 1, wherein the period of

time after ablation comprises one week.

6. The method for reducing stomach acid secretion of claim 1, wherein ablating tissue

comprises ablating at least a portion of a mucosal lining of the stomach.

7. The method for reducing stomach acid secretion of claim 1, wherein ablating tissue

comprises ablating cells that produce stomach acid.

8. The method for reducing stomach acid secretion of claim 1, wherein ablating tissue

comprises:

inserting an ablation probe to the stomach via an esophagus of the patient;

14

Inventors: Starkebaum and Prentice

Docket No.: P-11296.00

moving the ablation probe to a position proximate to a mucosal lining of the stomach;

and

activating the ablation probe to ablate at least a portion of the mucosal lining.

9. The method for reducing stomach acid secretion of claim 8, where the ablation probe comprises at least one of a radio frequency, laser, ultrasonic, microwave, thermal, chemical,

mechanical, and cryogenic ablation probe.

10. The method for reducing stomach acid secretion of claim 8, wherein activating the

ablation probe comprises delivering energy to the mucosal lining of the stomach via the

ablation probe.

11. The method for reducing stomach acid secretion of claim 8, wherein the ablation

probe comprises at least one electrode and wherein activating the ablation probe comprises

delivering electrical current to the mucosal lining of the stomach via the electrode.

12. The method for reducing stomach acid secretion of claim 11, wherein the ablation

probe comprises a conductive fluid delivery port adjacent the electrode, the method further

comprises delivering the conductive fluid to the mucosal lining of the stomach prior to

activating the ablation probe.

13. The method for reducing stomach acid secretion of claim 8, wherein the ablation

probe includes an optical waveguide and wherein activating the ablation probe includes

delivering energy from a laser to the mucosal lining via the optical waveguide.

14. The method for reducing stomach acid secretion of claim 8, wherein the ablation

probe includes a cryogenic probe and wherein activating the ablation probe includes

delivering cryogenic fluid to the mucosal lining via the cryogenic probe.

15

Inventors: Starkebaum and Prentice

Docket No.: P-11296.00

15. The method for reducing stomach acid secretion of claim 8, further comprising applying vacuum pressure to the mucosal lining to immobilize at least a portion of the mucosal lining.

16. The method for reducing stomach acid secretion of claim 8, wherein the catheter comprises an endoscope.

17. The method for reducing stomach acid secretion of claim 1, further comprising ablating additional stomach tissue based on a comparison of the second esophageal acid level to the first esophageal acid level.

18. An ablation system comprising:

a catheter inserted into a stomach of a patient with a hyperacid condition via an esophagus;

an ablation probe sized to fit the stomach inserted through the catheter and placed proximate a mucosal lining of the stomach;

an ablation source to control delivery of ablation energy via the ablation probe in an amount sufficient to ablate tissue within the stomach and inhibit acid production by the tissue; and

a pH monitor placed in one of an esophagus and a stomach of the patient to determine an acid level.

- 19. The ablation system of claim 18, wherein the pH monitor is placed in the esophagus to determine the acid level before ablation and a period of time after ablation.
- 20. The ablation system of claim 18, wherein the period of time after ablation comprises one week.
- 21. The ablation system of claim 18, wherein the pH monitor determines the acid level by monitoring a level of acid reflux.

Inventors: Starkebaum and Prentice

Docket No.: P-11296.00

22. The ablation system of claim 18, where the ablation probe comprises at least one of a radio frequency, laser, ultrasonic, microwave, thermal, chemical, mechanical, and cryogenic

ablation probe.

23. The ablation system of claim 18, wherein the ablation probe comprises at least one

electrode and wherein the ablation source delivers electrical current to the electrode.

24. The ablation system of claim 23, wherein the ablation probe further comprises a

conductive fluid delivery port adjacent the electrode, the system further comprises a

conductive fluid source to deliver fluid to the fluid delivery port.

25. The ablation system of claim 18, wherein the ablation probe comprises an optical

waveguide and wherein the ablation source delivers energy from a laser to the optical

waveguide.

26. The ablation system of claim 18, wherein the ablation probe comprises a cryogenic

probe and wherein the ablation source delivers cryogenic fluid to the cryogenic probe.

27. The ablation system of claim 18, further comprising a vacuum pressure source to

apply vacuum pressure to the mucosal lining of the stomach to immobilize at least a portion

of the mucosal lining.

28. An ablation system comprising:

means for ablating tissue within a stomach of a patient with a hyperacid condition to

inhibit acid production by the tissue; and

means for controlling the delivery of the ablation energy.

29. The ablation system of claim 28, further comprising means for determining a stomach

acid level of the patient.

17

Inventors: Starkebaum and Prentice

Docket No.: P-11296.00

30. The ablation system of claim 28, wherein the means for ablating tissue comprises at least one of a radio frequency, laser, ultrasonic, microwave, thermal, chemical, mechanical, and cryogenic means.